Physician profile
Rajiv K Nathoo
NPI 1588002059
$456,791.26
in general payments reported to CMS, 2019-2025
37 companies · $193K in 2025
The $193K reported for 2025 was more than what 99% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,315 · 2020: $1,193 · 2021: $1,903 · 2022: $2,513 · 2023: $65K · 2024: $192K · 2025: $193K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $373K · Travel and Lodging: $37K · Food and Beverage: $20K · Consulting Fee: $20K · Education: $384 · Honoraria: $8.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $373,044.25 |
| Travel and Lodging | $36,653.38 |
| Food and Beverage | $20,148.00 |
| Consulting Fee | $19,630.00 |
| Education | $383.97 |
| Honoraria | $8.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $227,544.07 | 2021-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $61,863.25 | 2021-2025 | Nemluvio, Aklief, Twyneo |
| Incyte Corporation | $58,235.52 | 2022-2025 | Opzelura, Opzelura |
| Janssen Biotech, INC. | $47,594.84 | 2019-2025 | Tremfya |
| Abbvie INC. | $38,952.13 | 2019-2025 | |
| Organon LLC | $12,667.22 | 2025 | Vtama |
| Ucb, INC. | $2,244.51 | 2020-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $758.72 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Novartis Pharmaceuticals Corporation | $717.70 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $676.29 | 2019-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $621.17 | 2019-2025 | |
| Leo Pharma INC. | $612.08 | 2019-2025 | Adbry |
| Sun Pharmaceutical Industries INC. | $549.98 | 2019-2025 | Ilumya, Winlevi, Absorica Ld |
| Dermavant Sciences, INC. | $491.52 | 2023-2024 | Vtama |
| Mayne Pharma Commercial LLC | $479.76 | 2019-2025 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajiv Nathoo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.